Twenty-One Years Later: The Research Chemical Interview That Predicted the Peptide Wars

In April 2005, I sat down with Citruscide to discuss a legal question that was beginning to surface across the Internet:

Could companies lawfully sell chemicals labeled “For Research Purposes Only” while knowing (or having obvious reason to know) that many purchasers intended to use them as drugs (to treat injuries or affect the structure or function of their bodies)?

The interview was prompted by the inception of a growing online fitness market for pharmaceutical products like tamoxifen and anastrozole, which are sometimes used in conjunction with steroid cycles. At the time, most products were accompanied by familiar disclaimers:

• “Research Use Only” or “RUO”
• “Not for Human Consumption”
• “For Laboratory Use Only”

Many vendors believed those words created a completely legal safe harbor.

I argued they did not.

Twenty-one years later, the recent FDA enforcement campaign against peptide vendors, research chemical companies, and non-approved GLP-1 marketers demonstrates that the legal principles discussed in that interview have aged remarkably well.

Not because the products remained the same.

They didn’t.

But because the law never changed.

The Disclaimers Were Never Protective

One of the biggest misconceptions in 2005 was the belief that FDA jurisdiction could be avoided simply by careful wording.

It couldn’t then.

It can’t now.

The Food, Drug, and Cosmetic Act has always focused on a product’s intended use, not merely the language printed on a label.

A disclaimer is one piece of evidence.

It is never the entire case.

The question has always been: What is the seller objectively intending these products to be used for?

That determination may come from virtually every aspect of the business.

• Website language.
• Emails.
• Social media.
• Videos.
• Customer instructions.
• Package inserts.
• Testimonials.
• Advertising.
• Bundle sales.
• Even the products sold next to each other.

Twenty-One Years Later, FDA Says Exactly the Same Thing

Recent FDA warning letters read almost like practical demonstrations of the principles discussed in that 2005 interview.

One 2026 warning letter involved a peptide company that repeatedly labeled products “Research Use Only” and “Not Intended for Human Consumption.”

Yet FDA concluded those products were unapproved drugs anyway.

Why?

Not because of the disclaimer.

Because of everything else.

The agency pointed to statements describing appetite suppression, weight loss, improved glucose handling, insulin sensitivity, and lipid metabolism.

It also noted that bacteriostatic water was being sold alongside injectable peptides, reinforcing the conclusion that the products were intended for human injection.

The disclaimer remained.

The evidence overwhelmed it.

That is how intended-use cases have always worked.

The Evidence Has Changed

The legal test is familiar.

The evidence is not.

Twenty years ago, investigators examined brochures, catalogs, websites, and customer correspondence.

Today they examine:

• Instagram posts
• TikTok videos
• Reddit discussions
• Podcasts
• YouTube demonstrations
• Facebook groups
• Influencer marketing
• Affiliate advertising
• Customer reviews

Modern businesses generate enormous amounts of evidence voluntarily.

In many investigations, companies document their own intended use better than any investigator ever could.

The Internet became the witness.

The GLP-1 Explosion Changed Everything

If there is one development that nobody fully anticipated in 2005, it was the emergence of GLP-1 medications.

Semaglutide.

Tirzepatide.

Retatrutide.

Entire industries emerged almost overnight.

Telemedicine.

Compounding.

Research chemical vendors.

Peptide websites.

Fitness influencers.

Longevity clinics.

As billions of dollars entered the market for Big Pharma, FDA increased scrutiny followed.

FDA may not have cared all that much about tamoxifen and anastrozole sold as research chemicals. But the agency seems to care a lot about GLP-1 products sold that way.

What Changed—and What Didn’t

The compounds changed.

The technology changed.

The marketing changed.

The economics changed.

Social media changed everything.

But the governing legal doctrine remained surprisingly constant.

The government still asks the same question it asked twenty years ago: What do the objective facts tell us about intended use?

Not what the disclaimer says.

What the business actually does.

The Lesson for Businesses

One lesson has become increasingly clear.

Compliance is not achieved by hiring a better copywriter.

It is achieved by aligning the entire business model with the law.

If every aspect of a company’s conduct points toward consumer drug use, no disclaimer will rescue it.

Conversely, a company whose practices genuinely reflect legitimate research distribution begins from a very different legal position.

The difference lies not in a few words on a label.

It lies in the totality of the evidence.

And Here’s the Twist

The “RUO” disclaimer was designed to be a protective talisman against the claim of intended use as a drug.

In other words, to be proof that the product was meant for some type of lab tests and not to be used on the bodies of the buyers.

But it didn’t protect anything.

Quite contrary: the Government regarded the disclaimer as evidence of the fraud.

The Government’s theory was – and still is – that the purpose of the disclaimer was and is to deceive the FDA into believing the lie that the intended use was for something other than as a drug.

RUO vendors nationwide have learned this to their chagrin when targeted by federal prosecutors.

Looking Forward

Ironically, this article is being written at a moment when federal policy regarding peptides may itself be evolving.

FDA’s Pharmacy Compounding Advisory Committee recently voted to recommend adding several peptides—including BPC-157, TB-500, KPV, and MOTS-c—to the 503A Bulks List for possible pharmacy compounding. Those votes are advisory only; they do not constitute FDA approval, nor do they eliminate the legal distinction between pharmacy compounding and the sale of research chemicals.

Whatever regulatory path ultimately emerges, one prediction from 2005 remains intact.

The words “For Research Use Only” have never been magic.

And after more than two decades, that remains the defining principle of research chemical law.